For best experience please turn on javascript and use a modern browser!
Bekijk de site in het Nederlands

Louis Jansen carries out research into the treatment of chronic hepatitis B (CHB). Currently, two types of drugs are approved for the treatment of CHB patients: conventional or pegylated interferon alpha (IFNα or Peg- IFNα) and nucleoside or nucleotide analogues (NAs). Jansen’s main focus is to establish predictors of response to Peg- IFNα-based therapy, which may ultimately allow the selection of those patients most likely to benefit from treatment and prevent unnecessary treatment in others.

Event details of Response to antiviral therapy in hepatitis B
Date 15 January 2016
Time 14:00 -15:00
Location Agnietenkapel
Room Location

L. Jansen: Virus-Host Interplay in Chronic Hepatitis B. Predicting Response to Immunomodulating Antiviral Therapy.

Supervisors

Prof. H.L. Zaaijer

Prof. U.H.W. Beuers

Co-supervisors

Dr H.W. Reesink

Dr N.A. Kootstra

Agnietenkapel

Room Location

Oudezijds Voorburgwal 229 - 231
1012 EZ Amsterdam

Entrance

This event is open to the public.